Aurisco expands Oligonucleotide capacity

The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.

Aurisco Pharmaceutical, an innovative pharmaceutical CRDMO (contract research, development and manufacturing organization) announced the expansion of its oligonucleotide manufacturing capacity.

The new OligoPilot 2000 solid-phase synthesizer, from Cytiva, completes Aurisco Biotech's pilot scale cGMP plant and provides immediate capacity availability to accelerate customer's clinical programs as well as Aurisco's generic oligonucleotide pipeline. The new website has been designed to offer a more user-friendly experience with more information, improved navigation and new communication functionalities. It allows visitors to explore the full CRDMO services, product portfolio and advanced technology toolbox and stay informed about the company.

"Aurisco has evolved from being a vertically integrated generic API manufacturer with fermentation and synthetic capabilities into a science based CRDMO, offering research, development and cGMP manufacturing of oligonucleotides, RNA conjugates, peptides and complex chiral small molecules. We're working with global organizations, Large Pharma, Biotechs and other CDMOs, Innovators and Generics, and felt the need to evolve our communication channels too. After launching our LinkedIn page last year, we have now launched a revised website, focused on the customer experience,” said Rafael Antunes, VP Business Development in Europe.